Inventor
BENNETT MARK K
US35 patents
⚠️ This page may combine multiple inventors who share the name “BENNETT MARK K”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RIGEL PHARMACEUTICALS INC
15 patentsUS7252952B2Aug 7, 2007
In vivo production of cyclic peptides for inhibiting protein—protein interaction
RIGEL PHARMACEUTICALS INC19 citations90
US6979549B2Dec 27, 2005
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC5 citations73
US7378248B2May 27, 2008
In vivo production of cyclic peptides for inhibiting protein-protein interaction
RIGEL PHARMACEUTICALS INC7 citations72
US7071190B2Jul 4, 2006
Inhibitors to tubulin polymerization
RIGEL PHARMACEUTICALS INC8 citations72
US7425418B2Sep 16, 2008
Compounds that modulate processes associated with IgE production
RIGEL PHARMACEUTICALS INC3 citations62
US7378251B2May 27, 2008
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein
RIGEL PHARMACEUTICALS INC2 citations62
US7604951B2Oct 20, 2009
Method for identifying compounds that modulate RXR associated processes with IgE production
RIGEL PHARMACEUTICALS INC1 citations51
US7598050B2Oct 6, 2009
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
RIGEL PHARMACEUTICALS INC1 citations51
US7563585B2Jul 21, 2009
Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)
RIGEL PHARMACEUTICALS INC0 citations51
US7422867B2Sep 9, 2008
Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7374894B2May 20, 2008
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7241581B2Jul 10, 2007
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
RIGEL PHARMACEUTICALS INC0 citations51
US7208289B2Apr 24, 2007
Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7189523B2Mar 13, 2007
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
RIGEL PHARMACEUTICALS INC0 citations51
US7141434B2Nov 28, 2006
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
RIGEL PHARMACEUTICALS INC0 citations51
ONYX THERAPEUTICS INC
10 patentsUS7691852B2Apr 6, 2010
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC65 citations99
US8431571B2Apr 30, 2013
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC33 citations96
US8357683B2Jan 22, 2013
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC34 citations96
US8609654B1Dec 17, 2013
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC8 citations84
US9511109B2Dec 6, 2016
Combination therapy with peptide epoxyketones
ONYX THERAPEUTICS INC10 citations80
US8765745B2Jul 1, 2014
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC1 citations63
US9657058B2May 23, 2017
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC0 citations52
US8735441B2May 27, 2014
Compounds for enzyme inhibition
ONYX THERAPEUTICS INC0 citations52
USRE47954EApr 21, 2020
Combination therapy with peptide epoxyketones
ONYX THERAPEUTICS INC0 citations48
US10596222B2Mar 24, 2020
Combination therapy with peptide epoxyketones
ONYX THERAPEUTICS INC0 citations48
SHENK KEVIN D
3 patentsCALITHERA BIOSCIENCES INC
3 patentsUS10258619B2Apr 16, 2019
Combination therapy with glutaminase inhibitors and immuno-oncology agents
CALITHERA BIOSCIENCES INC4 citations68
US10940148B2Mar 9, 2021
Combination therapy with glutaminase inhibitors and immuno-oncology agents
CALITHERA BIOSCIENCES INC0 citations57
US10195197B2Feb 5, 2019
Combination therapy with glutaminase inhibitors
CALITHERA BIOSCIENCES INC0 citations45